US3055882A - Reduction process for preparation of cyclic nitrogen compounds - Google Patents

Reduction process for preparation of cyclic nitrogen compounds Download PDF

Info

Publication number
US3055882A
US3055882A US819209A US81920959A US3055882A US 3055882 A US3055882 A US 3055882A US 819209 A US819209 A US 819209A US 81920959 A US81920959 A US 81920959A US 3055882 A US3055882 A US 3055882A
Authority
US
United States
Prior art keywords
alkylene
lower alkyl
imino
acid
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US819209A
Other languages
English (en)
Inventor
Mull Robert Paul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Corp
Novartis Corp
Original Assignee
Ciba Geigy Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Corp filed Critical Ciba Geigy Corp
Priority to US819208A priority Critical patent/US3006913A/en
Priority to US819209A priority patent/US3055882A/en
Priority to CH442861A priority patent/CH365079A/de
Priority to CH562160A priority patent/CH365081A/de
Priority to CH442961A priority patent/CH365080A/de
Priority to DEC21576A priority patent/DE1146062B/de
Application granted granted Critical
Publication of US3055882A publication Critical patent/US3055882A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms

Definitions

  • the present invention concerns a process for the preparation of guanidino compounds. More particularly, the procedure of the invention relates to the manufacture of (N,N-alkylene-imino)-lower alkyl-guanidines, in which alkylene contains from four to ten carbon atoms as ring members, and the salts thereof. Also anticipated are quaternary ammonium compounds and acyl derivatives of these compounds, whenever prepared according to the procedure of the invention.
  • N,N-alkylene-imino radicals containing from four to ten carbon atoms, primarily from six to eight carbon atoms, are unsubstituted, or may contain as further substituents of carbon atoms lower hydrocarbon radicals, such as lower alkyl, e.g. methyl or ethyl.
  • N,N-tetramethylene-imino (l-pyrrolidino), N,N-pentamethylene-imino (l-piperidino), N,N-hexamethylene-imino (l-hexahydro-azepino), N,N-heptamethylene-imino (l-octahydroazocino), N,N-octamethylene-imino (l-octahydro azonino), N,N-nonamethyleneimino (l-decahydro-azecino) or N,N-decamethyleneimino radicals.
  • the lower alkyl radical linking the alkylene-imino ring with the guanidino group, contains from two to seven carbon atoms and is represented by a lower alkylene radical, which may also be branched.
  • Such alkylene radicals contain preferably from two to three carbon atoms and are represented, for example, by 1,2-ethylene, 1-methyl-l,2 ethylene, 2-methyl-l,2-ethylene or 1,3-propylene; additional alkylene radicals are, for example, 2,3- butylene, 1,3-butylene, 1,4-butylene, 1,4-pentylene, 1,5- pentylene and the like.
  • the guanidino group is preferably unsubstituted.
  • the amino, as well as the irnino groups of the guanidino portion may be substituted by lower hydrocarbon radicals, such as lower alkyl, e.g. methyl or ethyl.
  • Such substituted guanidino groups are, for example, N- monomethyl-, N-polymethyl-, N-monoethyl or N-polyethyl-guanidino groups.
  • Salts of the compounds prepared according to the process of this invention are particularly therapeutically useful acid addition salts, such as those with inorganic acids, for example, hydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric or phosphoric acids, or those with organic acids, such as formic, acetic, propi onic, glycolic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, ascorbic, hydroxymaleic, dihydroxymaleic, benzoic, phenylacetic, 4-aminobenzoic, 4-hydroxybenzoic, anthranilic, cinnamic, mandelic, salicylic, 4- aminosalicylic, Z-phenoxybenzoic, 2- acetoxy-benzoic, methane sulfonic, ethane sulfonic, hydroxyethane sulfonic acid and the like.
  • hydrohalic acids e.g. hydro
  • the guanidine compounds may also form quaternary ammonium compounds, particularly those with lower alkyl halides, e.gl methyl, ethyl, propyl or isopropyl chloride, bromide or iodide, or lower alkyl lower alkane sulfonates, e.g. methyl or ethyl methane or ethane sulfonate, as well as the corresponding quaternary ammonium hydroxides and the salts which may be formed from the quaternary ammonium hydroxides by the reaction with inorganic acids other than hydrohalic acids or with orgahic acids, such as those outlined above for the preparation of the acid addition salts.
  • lower alkyl halides e.gl methyl, ethyl, propyl or isopropyl chloride, bromide or iodide, or lower alkyl lower alkane sulfonates, e.g. methyl or
  • Acyl derivatives of the guanidine compounds prepared according to the procedure of this invention are those 35,655,882 Patented Sept. 25, 1962 acids, e.g. trichloroacetic, hydroxyacetic or cyclopentyl-* propionic acid and the like, or lower alkenoic acids, e.g'.
  • monocyclic aromatic carboxylic acids e.g.- benzoic, hydroxybenzoic or aminobenzoic acid and the" like
  • bicyclic aromatic carboxylic acids e.g. l-naph thoic or Z-naphthoic acid and the like
  • carbocyclic aryl-lower aliphatic acids such as monocyclic carbocyclic aryl-lower alkanoic acids, e.g. phenylacetic acid or [3- phenylpropionic acid and the like
  • heterocyclic carboxylic acids for example, monocyclic heterocyclic carboxylic acids, e.g. nicotinic, isonicotinic or 2-furoic acid and the like.
  • the above-mentioned derivatives and salts thereof have antihypertensive properties and can be used as antihypertensive agents to relieve hypertensive conditions, particularly neurogenic or renal hypertension.
  • a particular characteristic of this antihypertensive effect is its long duration, which property is especially desirable in the treatment of chronic hypertensive states.
  • N,N-alkylene-imino-lower alkylguanidines in which the N,N-alkyleneimino iportion contains from six to eight, primarily seven, carbon atoms, and carries no additional substituents or only methyl groups, and in which lower alkyl, containing from two to three carbon atoms, separates the N,N-alkylene-imino portion from the guanidino group by two to three carbon atoms, and their salts with inorganic acids, such as mineral acids, e.g.
  • hydrochloric or sulfuric acid or with organic acids, such as hydroxy-substituted aliphatic acids, e.g. tartaric or citric acid, or unsaturated aliphatic acids, e.g. maleic acid.
  • organic acids such as hydroxy-substituted aliphatic acids, e.g. tartaric or citric acid, or unsaturated aliphatic acids, e.g. maleic acid.
  • This group is represented by the (N,N- heptamethylene-imino)-lower alkyl guanidines, particularly the guanidine compound of the formula:
  • the reduction of the carbonyl portion of the amide groups may be carried out by treatment with an aluminum hydride, particularly an alkali metal aluminum hydride, e.g. lithium aluminum hydride or sodium aluminum hydride, or an earth alkaline metal aluminum hydride, e.g. magnesium aluminum hydride, or aluminum hydride.
  • the reduction with these reagents is preferably performed in the presence of a solvent, particularly an ether, such as a di-lower alkyl ether, e.g. diethyl ether, a lower alkyl carbocyclic aryl ether, e.g. anisole, a di-carbocyclic aryl ether, e.g.
  • diphenyl ether or a cyclic ether, e.g. tetrahydrofurane or p-dioxane, and, if desired, at an elevated temperature and/or in the atmosphere of an inert gas, e.g. nitrogen.
  • an inert gas e.g. nitrogen.
  • the desired conversion may also be carried out by electrolytically reducing the amide derivatives on a cathode of a high overpotential such as a cadmium, zinc,
  • the catholyte used in such a reduction is preferably a mixture of water, sulfuric acid and a lower alkanoic acid, e.g. acetic or propionic acid.
  • a platinum, carbon, lead or stainless steel anode may be used; the anolyte is preferably sulfuric acid.
  • the starting materials used in the above reduction procedure may be prepared, for example, by treating a reactive functional derivative of an (N,N-alkylene-imino)- lower alkyl carboxylic acid or of a guanidino-lower alkyl carboxylic acid with a guanidino or an N,N-alkyleneimine, respectively, to form the desired amide compounds.
  • Reactive derivatives of carboxylic acids are, for example, esters, such as lower alkyl, e.g. methyl or ethyl, esters of activated esters, which are particularly useful for the formation of amide bonds, such as esters with reactive mercaptan compounds, e.g.
  • esters may be prepared according to procedures which are known for the manufacture of analogous esters.
  • Other reactive functional derivatives of acids are the acid addition salts of acid halides, particularly the hydrochloride of an acid chloride, which maybe prepared according to standard methods.
  • reaction of these reactive functional derivatives of carboxylic acids with the amino compounds may be carried out, for example, by treating a salt of an acid halide, particularly the hydrochloride of an acid chloride with the amine, preferably in a polar, but non-hydroxylated solvent, such as, for example, dimethylformamide, diethyleneglycol dimethylether, dioxane, tetrahydrofuran and the like.
  • a salt of an acid halide particularly the hydrochloride of an acid chloride
  • amine preferably in a polar, but non-hydroxylated solvent, such as, for example, dimethylformamide, diethyleneglycol dimethylether, dioxane, tetrahydrofuran and the like.
  • a modification of the above procedure comprises the converting in (N,N-alkylene-imino)-lower alkyl thiocarboxylic acid guanides or guanidino-lower alkyl thiocarboxylic acid N,N-alkylene-imides, the thiocarbonyl group of the thioarnide portion into a methylene group, and, if desired, carrying out the optional steps.
  • the replacement of the sulfur in the above-mentioned thioamides may be carried out by desulfurization, for example, with a freshly prepared hydrogenation catalyst, such as Raney nickel, in an alcoholic solvent, e.g. methanol or ethanol, if desired, in the presence of hydrogen, or electrolytically according to the procedure outlined hereinabove for the reduction of the amides.
  • a freshly prepared hydrogenation catalyst such as Raney nickel
  • an alcoholic solvent e.g. methanol or ethanol
  • the thioamides used as the starting materials in this modification may be prepared from the corresponding amides previously mentioned, for example, by treatment with phosphorus trisulfide or phosphorus pentasulfide.
  • a modification may consist in electrolytically reducing the amide in the presence of an alkali metal sulfide, e.g. sodium sulfide, thereby forming the thioamide as a nonisolated intermediate.
  • Another method to prepare the above described guanidino compounds comprises replacing in (2-R-l-N,N- alkylene-imino)-lower alkyl-guanidines, in which R represents an oxo group of the formula or a thiono group of the formula :8, such group by two hydrogen atoms, and, if desired, carrying out the optional steps.
  • oxo and thiono groups form together with the nitrogen atom of the N,N-alkylene-imino portion an amide or a thioamide group.
  • Such groups may be converted into the desired methyleneimino group by the previously described procedures; for example, an oxo group of an amide grouping may be replaced by two hydrogen atoms by treatment with an aluminum hydride, such as lithium aluminum hydride, or a thiono group of a thioamide grouping may be exchanged for two hydrogen atoms by desulfurization with a freshly prepared hydrogenation catalyst, such as Raney nickel. These reactions are carried out as previously shown.
  • the starting material used in this modification may be prepared, for example, by introducing into a 2-oxo-1- N,N-alkylene-imine an amino-lower alkyl radical, which may be accomplished, for example, by reacting an alkali metal, e.g. lithium or sodium, salt of the 2-oxo-1-N,N-
  • alkylene-imine with a cyano-lower alkyl-halide, e.g. chloride, and reducing in a resulting (2-oxo-l-l I,N-alkyleneimino)-lower alkyl nitrile the nitrile group to a methyleneamino group, which may be accomplished, for example, by treatment with a hydride, such as an aluminum hydride, e.g. lithium aluminum hydride.
  • a hydride such as an aluminum hydride, e.g. lithium aluminum hydride.
  • the 2-0240-1- N,N-alkylene-imine may also be reacted with a lower alkene-nitrile, e.g.
  • a resulting (2-oxo-1-N,N-alkylene-imino)-lower alkylguanidine compound may be converted to the (Z-thionol-N,N-alkylene-imino)-lower alkyl-guanidine, for example, by treatment with phosphorus trisulfide or phosphorus pentasulfide as shown hereinbefore.
  • a preferred group of compounds are (N,N-alkyleneimino)-lower alkyl carboxylic acid guanides, in which alkylene contains from six to eight carbon atoms, the lower alkyl carboxylic acid portion contains from two to three carbon atoms, separating the N,N-alkylene-imino portion from the guanidino group by two to three carbon atoms, and the guanidino group ,is otherwise unsubstituted.
  • This preferred group may be represented by the (l-N,N-heptamethylene-imino)-acetic acid guanide.
  • amide compounds may also be prepared by treating a reactive ester, formed by a hydroxy-lower alkyl carboxylic acid guanide with a strong acid, for example, a hydrohalic acid, e.g. hydrochloric acid, with the N,N- alkylene-imine, if desired, in the form of a salt, such as an alkali metal salt thereof.
  • a reactive ester formed by a hydroxy-lower alkyl carboxylic acid guanide with a strong acid, for example, a hydrohalic acid, e.g. hydrochloric acid
  • a strong acid for example, a hydrohalic acid, e.g. hydrochloric acid
  • a salt such as an alkali metal salt thereof.
  • Another group of valuable intermediates are the (N,N- alkylene-imino)-lower alkyl thiocarboxylic acid guanides, in which alkylene has the above-given meaning, and salts thereof.
  • These compounds are represented by the group of (N,N-alkylene-imino)-lower alkyl thiocarboxylic acid guanides, in which alkylene contains from six to eight carbon atoms, the lower alkyl thiocarboxylic acid portion contains from two to three carbon atoms, and separates the N,N-alkylene-imino portion from the guanidino group by two to three carbon atoms, and the guanidino group is otherwise unsubstituted; the (1-N,N-heptamethylene-imino)-thioacetic acid guanide illustrates this preferred group.
  • guanidino-lower alkyl carboxylic acid N,N-alkylene-imides in which alkylene has the above-given meaning, and salts thereof.
  • This series of intermediates is represented by the preferred group of guanidino-lower alkyl carboxylic acid N,N-alkyleneimides, in which alkylene contains from six to eight carbon atoms, the lower alkyl carboxylic acid portion contains from two to three carbon atoms, separating the N,N- alkylene-imino portion from the guanidino group by the same number of carbon atoms, and the guanidino group is otherwise unsubstituted.
  • the guanidino-acetic acid N,N-heptamethylene-imide represents this preferred group of compounds.
  • These compounds may also be prepared, for example, by treating a guanidine with a reactive ester, formed by a hydroxy-lower alkyl carboxylic acid N-N-alkylene-imide and a strong acid, such as a mineral acid, e.g. hydrochloric acid.
  • a reactive ester formed by a hydroxy-lower alkyl carboxylic acid N-N-alkylene-imide and a strong acid, such as a mineral acid, e.g. hydrochloric acid.
  • Such reactive esters are, for example, chloro-lower alkyl carboxylic acid N,N-lower alkylene-imides.
  • guanidino-lower alkyl thiocarboxylic acid N,N-alkylene-imides in which alkylene has the previously given meaning, and their salts are also part of the present invention. They are represented by the preferred group of guanidino-lower alkyl thiocarboxylic acid N,N-alkylene-imides, in which alkylene contains from six to eight carbon atoms, the lower alkyl thiocarboxylic acid portion contains from two to three carbon atoms, separating the N,N-alkylene-imino portion from the guanidino group by two to three carbon atoms, and the guanidino group is otherwise unsubstituted, and illustrated, for example, by the guanidino-thioacetic acid l-N,N-heptarnethylene-imide.
  • the (2-oxo-1-N,N-alkylene-imino)-lower alkyl-guanidines represent a further group of valuable intermediates, which may be illustrated by the preferred group of (2-oxo-1-N,N-alkylene-imino)-lower alkyl-guanidines, in which alkylene contains from six to eight carbon atoms, lower alkyl contains from two to three carbon atoms separating the guanidino group from the alkylene-imino portion by two to three carbon atoms, and the guanidino group is otherwise unsubstituted.
  • the 2 (2-oxo-1-'N,N-heptamethylene-imino)-ethyl-guanidine represents one of the preferred members.
  • (2-thiono-1-N,N-alkyleneimino)-lower alkyl guanidines in which alkylene has the previously given meaning, and the salts thereof.
  • a preferred group of these intermediates are the (Z-t-hiono-l- TN,N-alkylene-imino)-lower alkyl-guanidines, in which allkylene contains from six to eight carbon atoms and lower :alkyl from two to three carbon atoms separating the guanidino group from the alkylene-imino portion by two to three carbon atoms, whereas the guanidino group is otherwise unsubstituted.
  • This group may be represented by the 2-(2-thiono-1-N,N-heptamethylene-imino)-ethyl- .guanidine.
  • a combination of the two principal modifications of the process of the present invention may also be anticipated.
  • a (Z-oxo-l- ZN,N-alkylene-imino')-lower alkyl carboxylic acid guanide or of a guanidino-lower alkyl-carboxylic acid 2-oxo-1- N,N-alkylene-imide, in which alkylene has the abovegiven meaning with one of the reduction reagents previously described, the desired (N,N-alkylene-imino)- lower alkyl-guanidines described hereinbefore, may be formed.
  • the starting materials used in such a procedure may be prepared along the previously outline procedures by selecting the appropriate intermediates.
  • the above starting materials may be prepared according to the previously outline procedures by selecting the appropriate intermediates.
  • the guanidine compounds are obtained in the form of the free compounds or as the Salts thereof.
  • -A salt may be converted into the free compound in the customary way, for example, by treatment with an alkaline reagent, such as an aqueous alkali metal hydroxide, e.g. lithium, sodium or potassium hydroxide, an aqueous alkali metal carbonate, e.g. lithium, sodium or potassium carbonate or hydrogen carbonate, or aqueous ammonia.
  • a free base may be transformed into its therapeutically useful acid addition salts by reaction with an appropriate inorganic or organic acid, such as one of those outlined hereinabove, preferably in the presence of a solvent, such as a lower alkanol, e.g. methanol, ethanol, propanol or isopropanol, or an ether, e.g. diethylether or p-dioxane, and the like.
  • Acyl derivatives of the guanidine compounds of the present invention may be prepared, for example, by treat ing a resulting guanidine compound with the reactive derivative of a carboxylic acid, for example, with a halide, e.g. chloride, or with the anhydride of a carboxylic acid.
  • a halide e.g. chloride
  • the reaction is preferably carried out in an inert solvent, for example, in a hydrocarbon, such as an aliphatic hydrocarbon, e.g. hexane, or an aromatic hydrocarbon, e.g. benzene, toluene or xylene, or in a tertiary organic base, such as a liquid pyridine compound, e.g. pyridine or collidine.
  • a hydrocarbon such as an aliphatic hydrocarbon, e.g. hexane, or an aromatic hydrocarbon, e.g. benzene, toluene or xylene
  • a tertiary organic base such as a liquid pyridine compound, e.g. pyridine or collidine.
  • the guanidine compounds may be converted into the quaternary ammonium compounds by reacting the tertiary bases with an ester formed by a hydroxylated lower hydrocarbon compound with a strong inorganic or or ganic acid.
  • Hydroxylated lower hydrocarbon compounds contain from one to seven carbon atoms and the esters thereof are more especially those with mineral acids, e.g. hydrochloric, hydrobromic, hydriodic, or sulfuric acid.
  • esters are specifically lower alkyl halides, e.g. methyl, ethyl or propyl chloride, bromide or iodide, or lower alkyl lower alkane sulfonates, e.g.
  • the quaternizing reaction may be performed in the presence or absence of a solvent; suitable solvents are more especially lower alkanols, e.g. methanol, ethanol, propanol, isopropanol, tertiary butanol or pent-anol, lower alkanones, e.g. acetone or ethyl methyl ketone, or organic acid amides, e.g. formamide or dimethylformamide. If necessary, an elevated temperature and/ or a closed vessel may be employed.
  • suitable solvents are more especially lower alkanols, e.g. methanol, ethanol, propanol, isopropanol, tertiary butanol or pent-anol, lower alkanones, e.g. acetone or ethyl methyl ketone, or organic acid amides, e.g. formamide or dimethylformamide.
  • an elevated temperature and/ or a closed vessel may be employed.
  • the invention also comprises any modification of the general process wherein a compound obtainable as an intermediate at any stage of the process is used as starting material and the remaining steps(s) of the process is (are) carried out, as well as any new intermediates.
  • thiocarboxylic acid refers to a structure in which the sulfur is a thiono sulfur, i.e, double bonded to carbon.
  • Example 1 13.6 g. of chloroa-cetyl guanide is added while stirring to a solution of 22.6 g. of heptamethylene-imine in 200 ml. of benzene. After warming for one hour, and then cooling, the solution is filtered and the filtrate concentrated under reduced pressure.
  • Example 2 16.6 g. of 3 (2-oxo-1-N,N-hexamethylene-imino)- propionitrile is dissolved in absolute ethanol and hydrogenated over 2 g. of Raney nickel at a temperature of about and under pressure. After the necessary amount of hydrogen is taken up, the solution is cooled and the catalyst removed by filtration. The filtrate is treated with 13.9 g. of S-methyl-isothiourea sulfate; the mixture is refluxed until the evolution of methyl-mercaptan ceases. The solution is concentrated under reduced pressure, the residue is taken into water, aqueous sodium hydroxide is added, and the aqueous layer is extracted with ether.
  • the ether solution is dried and then added to a solution of 5 g. of lithium aluminum hydride in 500 ml. of ether.
  • the reaction mixture is refluxed overnight, the excess of 7 lithium aluminum hydride is decomposed by adding water and the reaction mixture is filtered.
  • the solvent is evaporated, and the residue, containing the 3-(N,N-hexamethylene-imino)-propyl-guanidine, is converted to the sulfate by adding dilute sulfuric acid and concentrating the aqueous solution.
  • the starting material may be prepared by slowly adding to a solution of 56.5 g. of caprolactam in 150 ml. of p-dioxane, 28 g. of acrylonitrile while stirring and cooling. A few drops of a strong base, such as benzyl trimethylammonium hydroxide, are added to initiate the reaction, and the temperature is maintained between 30- 35 for one-half hour. The mixture is allowed to stand for several days at room temperature, and is then acidified with hydrochloric acid. The residue, after evaporating the solvent, yields the desired 3-(l-N,N-hexamethyleneimino)-propionitrile by distillation, B.P. l33-l36/ 0.3
  • the lower alkyl thiocarboxylic acid portion has fr m two to three carbon atoms and separates the N,N-alkylene-imino portion from the guanidino group by two to three carbon atoms, and acid-addition salts thereof.
  • a member selected from the group consisting of (2-R-1N,N-alkylene-imino)-lower alkyl-guanidine, in which alkylene has six to eight carbon atoms, R is a member selected from the group consisting of 0x0 of the formula 0 and thiono of the formula :8, and lower alkyl has from two to three carbon atoms and separates the 2-R-l-N,N-alkylene-imino portion from the guanidino group by two to three carbon atoms, and addition salts thereof.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
US819209A 1959-06-10 1959-06-10 Reduction process for preparation of cyclic nitrogen compounds Expired - Lifetime US3055882A (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US819208A US3006913A (en) 1959-06-10 1959-06-10 Process for preparing (n,n-alkylene-imino)-lower alkyl-guanidines
US819209A US3055882A (en) 1959-06-10 1959-06-10 Reduction process for preparation of cyclic nitrogen compounds
CH442861A CH365079A (de) 1959-06-10 1960-05-17 Verfahren zur Herstellung neuer Guanidine
CH562160A CH365081A (de) 1959-06-10 1960-05-17 Verfahren zur Herstellung neuer Guanidine
CH442961A CH365080A (de) 1959-06-10 1960-05-17 Verfahren zur Herstellung neuer Guanidine
DEC21576A DE1146062B (de) 1959-06-10 1960-06-01 Verfahren zur Herstellung von Alkylen-iminoalkylguanidinen, deren Acyl-verbindungen,Salzen und quaternaeren Ammoniumverbindungen

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81921059A 1959-06-10 1959-06-10
US819208A US3006913A (en) 1959-06-10 1959-06-10 Process for preparing (n,n-alkylene-imino)-lower alkyl-guanidines
US819209A US3055882A (en) 1959-06-10 1959-06-10 Reduction process for preparation of cyclic nitrogen compounds

Publications (1)

Publication Number Publication Date
US3055882A true US3055882A (en) 1962-09-25

Family

ID=27420131

Family Applications (2)

Application Number Title Priority Date Filing Date
US819209A Expired - Lifetime US3055882A (en) 1959-06-10 1959-06-10 Reduction process for preparation of cyclic nitrogen compounds
US819208A Expired - Lifetime US3006913A (en) 1959-06-10 1959-06-10 Process for preparing (n,n-alkylene-imino)-lower alkyl-guanidines

Family Applications After (1)

Application Number Title Priority Date Filing Date
US819208A Expired - Lifetime US3006913A (en) 1959-06-10 1959-06-10 Process for preparing (n,n-alkylene-imino)-lower alkyl-guanidines

Country Status (3)

Country Link
US (2) US3055882A (de)
CH (3) CH365080A (de)
DE (1) DE1146062B (de)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3178433A (en) * 1963-05-07 1965-04-13 Ciba Geigy Corp 3-amino-1-diazacycloalkyl-alkyl-guanidines
US3213098A (en) * 1963-08-30 1965-10-19 Upjohn Co Amino substituted 3h-azepines and their preparation
US3250794A (en) * 1962-05-24 1966-05-10 Robert R Mod Fatty acid amides and esters thereof
US3252983A (en) * 1963-10-16 1966-05-24 Ciba Geigy Corp Aralkyl compounds
US3283003A (en) * 1960-12-23 1966-11-01 Smith Kline French Lab 2-(n-lower alkyl-n-cycloheptyl- and cyclooctylamino) ethyl guanidines
US4978684A (en) * 1987-11-13 1990-12-18 The Rockefeller University Method and agents for preventing staining of teeth
US4983604A (en) * 1987-11-13 1991-01-08 The Rockefeller University Inhibitors of nonenzymatic cross-linking
US5096703A (en) * 1984-03-19 1992-03-17 The Rockefeller University Method and agents for preventing staining of teeth
US5140048A (en) * 1984-03-19 1992-08-18 The Rockefeller University Inhibitors of nonenzymatic cross-linking
US5468777A (en) * 1984-03-19 1995-11-21 The Rockefeller University Method and agents for preventing and reversing the staining of teeth
US5612332A (en) * 1984-03-19 1997-03-18 Alteon Inc. Di- and triaminoguanidines, and methods of use
US5852009A (en) * 1984-03-19 1998-12-22 The Rockefeller University Compositions, including pharmaceutical compositions, for inhibiting the advanced glycosylation of proteins, and therapeutic methods based thereon
US5850840A (en) * 1995-11-15 1998-12-22 Alteon Inc. Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
US5877217A (en) * 1995-12-26 1999-03-02 Alteon Inc. N-acylaminoalkyl-hydrazinecarboximidamides
US6110968A (en) * 1995-12-26 2000-08-29 The Picower Institute For Medical Research Methods for treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
US6197830B1 (en) 1995-09-22 2001-03-06 Bruce M. Frome Method for achieving relief from sympathetically mediated pain

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278542A (en) * 1966-10-11
US3236859A (en) * 1966-02-22 Guanidinoalkyl)-pyrrolidine derivatives
US3185678A (en) * 1961-08-04 1965-05-25 Colgate Palmolive Co Polymethyleniminoalkylamides
SE321464B (de) * 1962-08-23 1970-03-09 Pharmacia Ab
US3245997A (en) * 1963-07-17 1966-04-12 Searle & Co 3-substituted 1-(1, 2, 3, 4-tetrahydro-2-isoquinolyl) alkyl-2-thioureas
US3317545A (en) * 1963-08-21 1967-05-02 Hoffmann La Roche [2-(2, 6-dimethylpiperidino)ethyl]guanidines and intermediates
US3364220A (en) * 1963-11-13 1968-01-16 Colgate Palmolive Co Heterocyclicaminoalkylguanidines
US3239517A (en) * 1964-10-12 1966-03-08 Toldy Lajos Phenothiazines having antihypertensive effect
FR2524887A1 (fr) * 1982-04-08 1983-10-14 Bouchara Emile Nouvelles cyanoguanidines, leur procede d'obtention et les compositions pharmaceutiques en renfermant
CZ284456B6 (cs) * 1992-02-15 1998-12-16 Hoechst Aktiengesellschaft Aminosubstituované benzoylguanidiny, způsob jejich přípravy, jejich použití jako léčiv a léčivo, které je obsahuje
US5212185A (en) * 1992-08-14 1993-05-18 G. D. Searle & Co. Piperidinyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE874447C (de) * 1944-08-22 1953-04-23 Bruno Dr Boettcher Verfahren zur Herstellung von 5-Thion-1, 2-dithiolen
US2846382A (en) * 1955-07-25 1958-08-05 Ciba Pharmacentical Products I New process for the preparation of amines
US2852528A (en) * 1958-09-16 Heterocyclic compounds and method
US2852510A (en) * 1954-03-03 1958-09-16 Ciba Pharm Prod Inc Heterocyclic compounds and process for producing same
US2909523A (en) * 1957-10-11 1959-10-20 American Cyanamid Co Substituted piperazines and method of preparing the same
US2957867A (en) * 1958-06-23 1960-10-25 Ciba Pharm Prod Inc 1, 5-benzodiazepin-4-ones and process of producing same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2852528A (en) * 1958-09-16 Heterocyclic compounds and method
DE874447C (de) * 1944-08-22 1953-04-23 Bruno Dr Boettcher Verfahren zur Herstellung von 5-Thion-1, 2-dithiolen
US2852510A (en) * 1954-03-03 1958-09-16 Ciba Pharm Prod Inc Heterocyclic compounds and process for producing same
US2846382A (en) * 1955-07-25 1958-08-05 Ciba Pharmacentical Products I New process for the preparation of amines
US2909523A (en) * 1957-10-11 1959-10-20 American Cyanamid Co Substituted piperazines and method of preparing the same
US2957867A (en) * 1958-06-23 1960-10-25 Ciba Pharm Prod Inc 1, 5-benzodiazepin-4-ones and process of producing same

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3283003A (en) * 1960-12-23 1966-11-01 Smith Kline French Lab 2-(n-lower alkyl-n-cycloheptyl- and cyclooctylamino) ethyl guanidines
US3250794A (en) * 1962-05-24 1966-05-10 Robert R Mod Fatty acid amides and esters thereof
US3178433A (en) * 1963-05-07 1965-04-13 Ciba Geigy Corp 3-amino-1-diazacycloalkyl-alkyl-guanidines
US3213098A (en) * 1963-08-30 1965-10-19 Upjohn Co Amino substituted 3h-azepines and their preparation
US3252983A (en) * 1963-10-16 1966-05-24 Ciba Geigy Corp Aralkyl compounds
US6114323A (en) * 1984-03-19 2000-09-05 The Rockefeller University Methods for inhibiting the advanced glycosylation of proteins
US5852009A (en) * 1984-03-19 1998-12-22 The Rockefeller University Compositions, including pharmaceutical compositions, for inhibiting the advanced glycosylation of proteins, and therapeutic methods based thereon
US5096703A (en) * 1984-03-19 1992-03-17 The Rockefeller University Method and agents for preventing staining of teeth
US5140048A (en) * 1984-03-19 1992-08-18 The Rockefeller University Inhibitors of nonenzymatic cross-linking
US5468777A (en) * 1984-03-19 1995-11-21 The Rockefeller University Method and agents for preventing and reversing the staining of teeth
US5612332A (en) * 1984-03-19 1997-03-18 Alteon Inc. Di- and triaminoguanidines, and methods of use
US4978684A (en) * 1987-11-13 1990-12-18 The Rockefeller University Method and agents for preventing staining of teeth
US4983604A (en) * 1987-11-13 1991-01-08 The Rockefeller University Inhibitors of nonenzymatic cross-linking
US6197830B1 (en) 1995-09-22 2001-03-06 Bruce M. Frome Method for achieving relief from sympathetically mediated pain
US6387957B1 (en) 1995-09-22 2002-05-14 Bruce M. Frome Preparation of topical regional compositions for the relief of pain
US20030060463A1 (en) * 1995-09-22 2003-03-27 Frome Bruce M. Preparation of topical regional compositions for the relief of pain
US6897241B2 (en) 1995-09-22 2005-05-24 Bruce M. Frome Preparation of topical regional compositions for the relief of pain
US5850840A (en) * 1995-11-15 1998-12-22 Alteon Inc. Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
US5877217A (en) * 1995-12-26 1999-03-02 Alteon Inc. N-acylaminoalkyl-hydrazinecarboximidamides
US6110968A (en) * 1995-12-26 2000-08-29 The Picower Institute For Medical Research Methods for treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts

Also Published As

Publication number Publication date
CH365079A (de) 1962-10-31
CH365080A (de) 1962-10-31
CH365081A (de) 1962-10-31
US3006913A (en) 1961-10-31
DE1146062B (de) 1963-03-28

Similar Documents

Publication Publication Date Title
DE3788878T2 (de) Verfahren zur Herstellung von optisch aktiven Benzolsulfonamidderivaten.
SU1333234A3 (ru) Способ получени производных N-фенилбензамида или их солей
RU2154639C2 (ru) Производные пиперазинов, способы их получения и фармацевтическая композиция
CH365079A (de) Verfahren zur Herstellung neuer Guanidine
SU526292A3 (ru) Способ получени производных 8-азапурин-6-она
US3178433A (en) 3-amino-1-diazacycloalkyl-alkyl-guanidines
EP0192255B1 (de) Bi-2H-pyrroli(di)ndione
CH621772A5 (de)
US3078272A (en) N-aza-bicyclo-alkylene-imino
US2989533A (en) Basically substituted diphenyl-carbinol esters and a process for preparing them
US3139455A (en) Phenoxyacetamidoximes
US3030378A (en) Five-membered nu-heterocyclic guanidines
US3320247A (en) Phenthiazine compounds
US3254094A (en) 3-imino-2, 1-benzisothiazoles
US3551414A (en) 6,7-dihydro-5h-dibenz(c,e)azepin-7-ones
EP0114033A1 (de) Substituierte Azabicycloalkane, ihre Verwendung, pharmazeutische Präparate, welche diese Verbindungen enthalten, und Verfahren zur Herstellung dieser Verbindungen
US3509162A (en) Phenethyl carbamates
US4235921A (en) Treating muscular spasms and convulsions with 3-azabicyclo[3.1.0]hexanes
EP0166692B1 (de) Substituierte Azabicycloheptane, ihre Verwendung, pharmazeutische Präparate, welche diese Verbindungen enthalten, und Verfahren zur Herstellung dieser Verbindungen
US3200132A (en) Aminomethyl-benzofurans
Perjési et al. Synthesis of partially saturated N-substituted 4 H-3, 1-benzothiazine-2 (1 H)-thiones
US2963486A (en) Certain bis-(alkylaminomethyl)-pyridines
US3423415A (en) 4 - (n - (3,3 - diphenyl - propyl) - amino) - 1-methyl-3-phenyl-piperidine and intermediates thereto
US3202712A (en) 1-cyclohexene-4-bis (omicron-chlorobenzylaminomethyl) and derivatives
US4284557A (en) Intermediate racemates for the preparation of biotin and a process for their preparation